Chargement en cours...
Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer
PURPOSE: To evaluate the prognostic value of prostate-specific antigen nadir (nPSA) after high-dose-rate (HDR) brachytherapy in clinically non-metastatic high-risk prostate cancer patients. MATERIAL AND METHODS: Data from 216 patients with high-risk or locally advanced prostate cancer who underwent...
Enregistré dans:
| Publié dans: | J Contemp Brachytherapy |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Termedia Publishing House
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4873555/ https://ncbi.nlm.nih.gov/pubmed/27257412 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5114/jcb.2016.59686 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|